Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
about
Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver diseaseConcise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infectionDaclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-AnalysisIndian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis.Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.New Therapies for Hepatitis C Virus Infection.The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, VietnamHepatitis C Virus and Liver Transplantation.The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver diseaseA real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies.Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.Sofosbuvir based therapy in hepatitis C patients with and without cirrhosis: Is there difference?Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.Projections of primary liver cancer to 2030 in 30 countries worldwide.Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.The future of liver transplantation for viral hepatitis.Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review.Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.Interferon-free treatment for HCV-infected patients with decompensated cirrhosis.Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.When and How to Treat HCV Infection with the New Antivirals before or after Liver Transplantation.Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States.Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment.Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?The oncologic burden of hepatitis C virus infection: A clinical perspective.Impact of etiological treatment on prognosis.Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy.IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting.Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markers.Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era.Occurrence and Recurrence of Hepatocellular Carcinoma After Successful Direct-Acting Antiviral Therapy for Patients With Chronic Hepatitis C Virus Infection.The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes.Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort.
P2860
Q26752433-AD3C5633-8109-419A-957F-B81D2CABE4B3Q28075544-A9B37AD8-08C4-43E2-A5DD-80B647F5F465Q28077287-53E05530-422E-4D5D-8049-A1DD01187F60Q30355190-B315F72E-E5BF-4160-A670-8473CC47A271Q30399476-CB29621C-617B-4917-BFFB-4FBA00D55A08Q30841159-C084A9B7-1A0F-4ECD-A07F-6B22B2381EE5Q31160142-3C976E8F-C447-4881-B59A-981E0C58BA5DQ33560181-7B42F5AE-1CF4-41F4-8D7D-C48EDD1EE7DDQ33663998-C7CABAC0-1790-4BA8-8496-11ACF4A0D2C8Q33717116-8D5B302B-9C1D-48AD-AC4A-F1596663A739Q36243096-6475F5A8-3B3B-4B7E-A5AA-56E38E403DF5Q37279260-18020E7F-44F3-416E-B929-860FB9880839Q37398996-BD14420B-EAA8-4E2E-A266-49A39EB2988BQ37723615-2179E135-3A07-4D4C-8CDB-4021C78A1CE4Q38632730-53BF0EC4-59B2-48F4-876A-46A7B8A99E21Q38634903-5A5507BB-4030-484A-86FF-48C5DEDCB9ECQ38635796-39DA520F-EA62-4FA5-8336-76938E53F085Q38748387-E2253EEF-B7D7-47AA-8089-62B619206BEAQ38758591-1952A831-E787-4A26-BCAA-9BE500BCA0DDQ38763789-7DCA35F1-1592-446F-B93A-016146CD3CD2Q38774864-9486CBE8-AE84-4E07-8E7B-9B39692F2FDFQ38786225-7AB9CF15-7256-4FF9-9F04-C3835150E7E8Q38798716-5B4F4CFF-10C0-437D-9506-FF0EC67F1815Q38860565-B4405A1C-017F-4FA0-8897-E72C2744578DQ38972499-142FDA44-FBEC-4485-91C2-47CBE273C20EQ38976820-1414ED01-E409-4A69-BA43-137315BBEF4AQ39010715-FC86064E-0FB0-4F1B-935B-437F41CE5A5AQ39025575-72EB6181-B084-4FAC-8111-BE25B4FED22DQ39066393-00D4F403-970D-429C-93CF-34EDFE67B864Q39067369-88B2ABF2-BA3B-4AAE-9E8B-6C84634040A6Q39203624-133AC17F-7043-4197-BEBB-A9B1110A13AFQ39418450-C599B848-75D3-4D45-85BE-EA75AD134D1EQ39431994-2B0F4B08-1942-4166-B24C-885ABDDF7F34Q39513661-F2B10477-32FE-475D-B700-5457EE01A90EQ39612358-A516D03A-93A2-490A-A61D-43DC83F56E6AQ39771933-C826CB80-71C5-45F6-AEB2-A515D6BB6D21Q40051943-0A726CFE-BD9B-42F2-B88B-E98EAF7FC7CCQ40059588-6DA20CDF-5D7F-4A18-BC0E-5AEB314160BCQ40086306-6E01EAEE-40B7-4229-8F09-D94D0F6D1B81Q40121053-D98F23FE-92EE-448E-A44F-D0B0A7A373D8
P2860
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Impact of direct acting antivi ...... C and decompensated cirrhosis.
@en
type
label
Impact of direct acting antivi ...... C and decompensated cirrhosis.
@en
prefLabel
Impact of direct acting antivi ...... C and decompensated cirrhosis.
@en
P2093
P50
P1476
Impact of direct acting antivi ...... C and decompensated cirrhosis.
@en
P2093
Ashley Brown
David J Mutimer
Douglas C MacDonald
Graham R Foster
HCV Research, UK
John McLauchlan
Kosh Agarwal
Suman Verma
William T H Gelson
P304
P356
10.1016/J.JHEP.2016.01.029
P577
2016-01-29T00:00:00Z